Zhang Financial LLC Buys 5,323 Shares of Medtronic PLC $MDT

Zhang Financial LLC grew its stake in shares of Medtronic PLC (NYSE:MDT) by 20.0% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 31,978 shares of the medical technology company’s stock after acquiring an additional 5,323 shares during the period. Zhang Financial LLC’s holdings in Medtronic were worth $3,046,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of MDT. Brighton Jones LLC grew its position in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after acquiring an additional 381 shares in the last quarter. Bessemer Group Inc. increased its position in Medtronic by 31.4% during the 2nd quarter. Bessemer Group Inc. now owns 1,363,264 shares of the medical technology company’s stock valued at $118,836,000 after purchasing an additional 326,117 shares during the period. Rossby Financial LCC raised its holdings in shares of Medtronic by 7.7% in the 2nd quarter. Rossby Financial LCC now owns 2,044 shares of the medical technology company’s stock valued at $178,000 after purchasing an additional 147 shares in the last quarter. Finally, Advisory Alpha LLC lifted its position in shares of Medtronic by 15.5% in the 2nd quarter. Advisory Alpha LLC now owns 2,663 shares of the medical technology company’s stock worth $232,000 after purchasing an additional 357 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

MDT opened at $96.85 on Wednesday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The firm has a 50 day moving average of $99.01 and a two-hundred day moving average of $96.83. The firm has a market capitalization of $124.16 billion, a PE ratio of 26.98, a P/E/G ratio of 2.48 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio is currently 79.11%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic said it will spin off its Diabetes segment via an IPO of MiniMed, positioning the business as a standalone diabetes-care company — a move investors often view as a value-unlocking separation that sharpens Medtronic’s focus on higher-margin therapy areas. Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval
• Positive Sentiment: MiniMed launched an IPO roadshow for 28 million shares and is marketing the offering for a potential March pricing; successful execution would deliver up to ~$784M in proceeds and create a separately investable diabetes franchise. MiniMed announces launch of IPO roadshow
• Positive Sentiment: Reports show MiniMed is pricing the IPO at $25–$28 per share (28M shares) — implying a roughly $7.8B equity valuation at the top end — which frames expectations for how much value might be separated from MDT’s balance sheet. Medtronic’s MiniMed prices IPO at up to $784M
• Positive Sentiment: Medtronic received FDA clearance for the Stealth AXiS surgical system (new spine-surgery platform), adding an addressable-market product that could support med-tech organic growth over time. Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval
• Neutral Sentiment: Analysts and market commentary note MDT has been rangebound for years; some bullish commentary (TipRanks) says an “inflection trade” could reappear if execution and separation proceed smoothly. Why the Medtronic (MDT) ‘Inflection Trade’ is Back On
• Neutral Sentiment: Medtronic highlighted sustainability and product-packaging improvements — positive for ESG positioning but unlikely to move near-term fundamentals. Improving Sustainability in Packaging & Products
• Neutral Sentiment: BTIG and other outlets maintained cautious/hold views; Truist cut its price target slightly (from $107 to $103) but kept a Hold — mixed analyst stance means near-term reactions may be muted. Medtronic plc (MDT) Gains Momentum Through Diabetes and Cardiovascular Operations
• Negative Sentiment: Analyst action is lukewarm: a modest price-target cut and multiple “hold” ratings suggest limited buy-side conviction until the MiniMed separation and product rollouts show clear results. BTIG Sticks to Its Hold Rating for Medtronic (MDT)

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. CICC Research assumed coverage on Medtronic in a research report on Friday, January 30th. They issued an “outperform” rating for the company. Barclays reaffirmed an “overweight” rating and set a $118.00 price objective on shares of Medtronic in a research report on Wednesday, February 18th. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Finally, Citigroup started coverage on Medtronic in a research report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus target price of $110.84.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).